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ABSTRACT
Inhibition  of protein synthesis  by puromycin  (100  y/ml)  is known  to  inhibit the  synthesis
of  ribosomes.  However,  ribosomal  precursor  RNA  (45S)  continues  to  be  synthesized,
methylated,  and  processed.  Cell  fractionation  studies  revealed  that,  although  the  initial
processing  (45S  -t  32S  +  16S)  occurs  in  the  presence  of puromycin,  the  16S  moiety  is
immediately  degraded.  No  species of ribosomal RNA  can be  found  to have emerged  from
the nucleolus.  The  RNA  formed  in  the  presence  of puromycin  is  normal  as judged  by its
ability  to  enter  new  ribosomal  particles  after  puromycin  is  removed.  This  sequence  of
events is not a result of inhibition  of protein synthesis,  for  cycloheximide,  another inhibitor
of protein synthesis, either  alone or in  combination with puromycin  allows the completion
of new ribosomes.
It  has  been  found  in  cultured  mammalian  cells
that,  even  after the inhibition  by cycloheximide  of
more  than  99%  of  cell  protein  synthesis,  new
ribosomal  RNA  can  be  synthesized  and  incor-
porated  into  ribosomes  which  enter  the  cell
cytoplasm  (Warner  et  al.,  1966  a).  These  experi-
ments  indicate  that  in  HeLa  cells  there  exists  a
pool  of ribosomal  proteins  which  can  be  used  to
assemble  ribosomes  in  the  absence  of continuing
protein synthesis  (Warner,  1966).  In light of these
findings  it  was  somewhat  surprising  that  puro-
mycin,  another agent which has  been widely used
as  a suppressor of protein synthesis  in both  animal
and bacterial  cells,  was found  to have a drastically
different  effect  from  cycloheximide  on  the  syn-
thesis  of  ribosomes  in  HeLa  cells  (Latham  and
Darnell,  1965;  Warner,  et  al.,  1966  a).  Although
the  synthesis  of  45S  ribosomal  precursor  RNA
molecules  appeared  to  continue  after  cells  had
been  exposed to puromycin,  none of this precursor
RNA  ever  appeared  in  ribosomal  subunits  in
the cell cytoplasm.
Newer  cell  fractionation  techniques  (Penman,
1966;  Penman  et  al.,  1966;  Soeiro  et  al.,  1966;
Vaughan  et  al.,  1967  a)  have  now  allowed  an
examination  of  ribosome  biosynthesis  at  several
points  between  the  synthesis  within  the  nucleolus
of  the  45S  ribosomal  precursor  RNA  molecule
and  the eventual  appearance  of new  cytoplasmic
subribosomal  particles.  This  report  describes  a
detailed  analysis of the  effect of puromycin  on  the
various stages of ribosome  manufacture  which can
at present be observed.
METHODS  AND  MATERIALS
Cells and Labeling Procedures
The  growth,  labeling,  and  harvesting  of  suspen-
sion  cultures  of  HeLa  cells  were  performed  as  has
been  described  previously.  (Eagle,  1959;  Warner  et
al.,  1966 b).
SOLUTIONS:  Composition  and  designation  of
solutions  employed  were  as  follows:  RSB,  reticulo-
cyte  standard  buffer,  0.01  M NaCI,  0.01  M Tris  (pH
7.4),  0.0015  M MgCI 2;  HSB,  high  salt buffer,  0.5 M
NaCl,  0.05  M MgCI 2, 0.01  M Tris  (pH  7.4);  SUT,
910.5%  SDS,  0.5 M urea,  0.01  M  Tris  (pH 7.4); NETS
0.1  M NaCI. 0.01  M  EDTA  (pH  7.0),  0.01  M  Tris  (pH
7.4),  0.2%  SDS.
Cell Fractionation
The  preparation  of cytoplasmic  extracts  in  RSB,
the  detergent  treatment  of  nuclei,  and  subsequent
subfractionation  of  nuclei,  for  the  yielding  of  a
"pellet  fraction"  containing  the  nucleoli  and  a
"nuclear  supernatant"  fraction,  have  been  described
previously  (Penman,  1966;  Soeiro  et  al.,  1966).
Release and Sedimentation Analysis of RNA
RNA  was  released  from  cytoplasmic  extracts  by
SDS-EDTA  treatment  as  has  been  previously  de-
scribed (Girard,  1964).  It was found that RNA in the
nuclear  pellet  fraction  could  be  quantitatively  re-
leased  by  resuspension  in  SUT.  Ribosomal  RNA
from  nuclear  supernatant  preparations  in  HSB was
quantitatively  released  in  the  presence  of  1%  SDS
and 0.1  M EDTA (Vaughan  et  al.,  1967 a).  However,
the quantitative  release  of heterogeneously  sediment-
ing  nuclear  RNA  from  the  nuclear  supernatant
requires  deproteinization  by  hot  phenol  in  the
presence  of SDS  (Soeiro et  al.,  1966).
Isolated  RNA  was  subjected  to  sedimentation
analysis  on  sucrose  gradients  (15-30%  w/w  sucrose
dissolved  in  NETS  buffer)  as  has  been  previously
described  (Penman  et  al.,  1964).  Details  are given  in
legends.
MATERIALS:  Uridine-
3H, 20mc/,umole,  was pur-
chased  from  Nuclear-Chicago  Corporation,  Des
Plaines,  Ill.;  and  methyl-'
4C-labeled  methionine,
10-50 /c//imole;  and  uridine-
14C,  30  uc/j/mole,  from
New  England  Nuclear  Corp.,  Boston,  Mass.  Puro-
mycin  dihydrochloride  was  purchased  from  Nutri-
tional  Biochemicals  Corporation,  Cleveland,  0.  and
cycloheximide  (Actidione)  from  Upjohn  Co.,  Kala-
mazoo,  Mich.
RESULTS
Formation  of 45S RNA  in
Puromycin-Treated Cells
Considerable  evidence  from  this  and  other
laboratories  (Scherrer  et  al.,  1963;  Perry,  1964;
Rake  and  Graham,  1964;  Girard  et  al.,  1965;
Penman,  1966;  Penman  et  al.,  1966;  Warner
et  al.,  1966  b) has  provided  the  following  scheme
of  the  synthesis  of  ribosomal  RNA  and  its  as-
sembly into ribosomal particles in cultured  animal
cells.  This  is  summarized  in  Fig.  1, in  which  the
operations  necessary  for  examination  of each  cell
fraction  are  also  outlined.  The  synthesis  within
the nucleolus  of a large molecule  of RNA,  the 45S
ribosomal  precursor  RNA,  is  the  first  observable
stage  of  rRNA  (ribosomal  RNA)  manufacture.
After  addition  of methyl  groups  to  the  45S  poly-
nucleotide  chain  (Greenberg  and  Penman,  1967;
Zimmerman  and  Holler,  1967),  this  molecule  is
cleaved  and yields 32S  and  16S  moieties. The  16S
species  is  rapidly  assembled  into a ribonucleopro-
tein  subribosomal  particle  and  in  less  than  5
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FIGURE  1  Scheme  for  biosynthesis  of ribosomes  in HeLa  cells.  The  diagram  presents  the  flow  of
rRNA  molecules  (labeled  45S,  3S,  28S,  16S,  and  5S)  from  the  point  of  synthesis  in  the
nucleolus  through  the  maturation  process  whereby  rRNA  becomes  associated  with  protein  to  form
particles.  After  cell  rupture  in  hypotonic  medium,  the  nucleus  of  the  cell  is  isolated  from  the
cytoplasm  by  centrifugation.  The  nucleus  is  subsequently  treated  with  detergent,  lysed  in  a  high
salt  DNase  mixture,  and  then  divided  by  centrifugation  into  a  nuclear  pellet,  containing  the
nucleoli,  and  a  nuclear  supernatant  fraction.  See  text for  details  of methods  and references.
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subribosomal  particle.  The  32S  species  is further
modified  so that it sediments  as  28S  rRNA which
then  appears  in  a  larger  subribosomal  nuclear
particle.  A  lag  period  of  approximately  15-30
min  exists  before  this  larger  (60S)  subribosomal
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particle  appears  in  the  cytoplasm.  As  is shown  in
Fig.  1,  both  the  large  and  small  nuclear  sub-
ribosomal  particles  are  detected  in  the  nuclear
supernatant  (Vaughan  et  al.,  1967  a).  Whether
this  is  the  true  intranuclear distribution  or repre-
sents  loss  of  these  particles  from  the  nucleolus
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FIGURE  2  RNA synthesis in puromycin-treated  cells. A  growing culture  of HeLa  cells was divided  (-5
min),  and  one-half  was  treated  for  5  min with  puromycin.  At time  0,  both  cultures  were  labeled  with
uridine-
3H  (0.5  c  ml, 20 mc/gmole)  for  5 min followed  by the addition of  unlabeled  nucleosides  (final
concentrations  uridine  0.1 mM,  cytidine  0.05 mM,  and thymidine  0.05  mM).  One sample  (a)  was taken at
+15  min and  another  (b,  d, e)  at  +75  min.  The cell samples  were  then  subjected to cell  fractionation
followed  by RNA extraction and sedimentation analysis  of the various subcellular fractions  (See Methods
and Materials).  In all samples radioactive  RNA from cell fractions of control  cells is indicated by  O  and
that from puromycin-treated  cells  by  . The solid  lines  in a and  d indicate  the  OD 2 60  tracings  of the
control samples  which were  identical with those  from the  puromycin-treated  samples. The  positions of all
peaks in this figure  and  subsequent  figures  was determined  by  comparing  them with major peaks in  the
OD 260  tracings. The  OD260 profile,  however,  is only  given  in a and d  of this  figure,  for  the sake  of sim-
plicity.  a,  nuclear  pellets  +15  min;  b,  nuclear  pellets  +75  min;  d, nuclear  supernatant  +75  min;  e,
cytoplasm  +75  min.
For  comparison  of  the over-all  sedimentation  profiles  of  the  radioactive  RNA  in  the  nuclear  pllet
fractions  (a and  b)  the cpm  in  the puromycin  samples  have  been  multiplied  by  four for  a  and  by  two
for  b.  c represents  an analysis  of  the RNA  of the nuclear  pellet  of cells  treated  with  puromycin  for  60
min before a  40 min exposure  to uridine-'
4C  (0.01  pc/ml; 30 /c//Amole).
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(iduring  the  nuclear  fractionation  has  not  been
established.  Also  depicted  in  the  diagram  is  the
recent  finding  that  5S  RNA,  a  newly  discovered
"structural"  RNA (Rosset et al.,  1964;  Knight and
Darnell,  1967),  joins  the larger ribosomal  subunit
before  it leaves  the nucleus.
Fig.  1  further  illustrates  that  newly  formed
ribosomal  subunits  first  enter  the  cytoplasm  as
subunits  and  then  are  found  in  polyribosomes.
Later they are found in single ribosomes. Although
it  has  been  established  that  there  is  eventual
equilibrium  between  free  subunits  (Vaughan
et  al.,  1967  a),  free  74S  ribosomes,  and  the ribo-
somes in polysomes,  the mechanism by  which  this
equilibrium is  accomplished  is  at present  obscure.
The  over-all  process  of ribosomal manufacture
in HeLa  cells,  as tested  by the  appearance  in  the
cytoplasm  of subribosomal particles bearing  newly
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formed  rRNA,  has  been  shown  to  be  suppressed
by  puromycin  treatment  (Latham  and  Darnell,
1965;  Warner  et  al.,  1966  a).  With  newer  tech-
niques it  is possible,  as outlined  above,  to observe
several stages in the biosynthesis  of ribosomes  prior
to cytoplasmic  appearance.  Therefore,  an attempt
was made  to  locate the  stage  at which  puromycin
exerted  its  inhibition  of  the  proposed  scheme  of
ribosome  synthesis.
Previous  experiments  have  shown  that,  when
actinomycin  D  is added  to  previously labeled  cells
at  the  time  the 45S RNA  is the  dominant  labeled
RNA  species,  no  further incorporation  into  RNA
takes  place  and  that  the  45S  RNA  disappears
while  32S  (ultimately  28S)  and  16S rRNA  appear
(Scherrer  et  al.,  1963;  Warner  et  al.,  1966  b;
Penman,  1966).  In addition,  the  45S  molecule  is
the only rapidly  labeled RNA species with the ap-
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FIGURE  3  Dose dependence  of  puromycin  inhibition  of ribosome  formation.  Logarithimically  growing
HeLa  cells were  preincubated for  5  min with puromycin  at final  concentrations  of 0  (a, a'), 5  (b,  b'),  20
(c,  c'),  or  100  y/ml  (d,  d'),  and then  (in  the continued  presence  of  the drug)  labeled  for  75  min  with
uridine-3H  as  in Fig.  2.  Each  culture  was  fractionated,  and  the newly  synthesized  radioactive  RNA  in
the nuclear pellet  (a,  b,  c,  d) and  "cytoplasmic"  (a', b', c', d') fractions  analyzed as  in Fig.  2.  In this  and
all  subsequent experiments  nuclear pellet  RNA labeled  with a uridine  precursor  was released  with SUT
and the nuclear  supernatant and  cytoplasmic fractions  with SDS (0,  cpm).
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FIGURE  4  Fate  of  RNA accumulated  in  the presence  of puromycin  after  removal  of  drug.  HeLa  cells
were preincubated  for 5  min with puromycin  100  y/nml and  then labeled  with  uridine-
1 4C  (30  Ac/pmnole;
0.02  c/ml)  in  the presence  of the drug.  After  30 min,  aetinomycin  D  (5  y/ml)  was added to the  cul-
ture  and the  cells  were  washed  free  of puromycin  by centrifugation  (800  g for  3  min  at 37
0C) and  re-
suspension  in fresh  medium  containing  actinomycin  D.  After  60  min  of  further  incubation  the  cells
were  fractionated  and  the  radioactive  RNA  was  analyzed  as  before.  a,  nuclear  pellet;  b,  nuclear  su-
pernatant;  c,  cytoplasm.
propriate,  high guanosine plus  cytosine content  to
serve  as  a precursor  to  ribosomal RNA  (Soeiro  et
al.,  1966).  It  was therefore  concluded  earlier  that
45S  RNA  is  a  precursor  to  both  28S  and  16S
rRNA.  Fig.  2  shows  an  experiment  in  which  cells
had been preincubated  for  5 min  with puromycin
(100  y/ml)  and  then  labeled  with  uridine-
3H  (5
min  pulse  followed  by a  "chase"  with  unlabeled
nucleosides).  RNA from various  cell fractions was
then  examined  by  sedimentation  analysis.  The
nuclear pellet or nucleolar  fraction of cells exposed
to uridine-
3H for a total of 20 min contained  newly
synthesized  RNA  which  sedimented  as  a  sharp
peak at 45S just as did RNA released  from normal
cells  (Fig.  2  a).  Furthermore  (Fig.  2  b),  after  a 75
min exposure  to uridine-
3H  both  labeled  45S  and
32S  ribosomal  precursor  RNA  were  found  in the
nucleolus  of puromycin-treated  cells,  but,  unlike
the  control  culture,  28S  or  16S  RNA  was  un-
labeled  in both  the nuclear  supernatant  (Fig.  2  d)
and the  cytoplasm  (Fig. 2  e). When  the 32S  RNA
appeared  in  the control  culture,  radioactive RNA
totaling  about one-third  the number  of counts  in
the  32S peak  was observed  in the  16S RNA  of the
cytoplasm  and  the  nuclear  supernatant.  In  the
puromycin-treated  culture,  no  radioactive  16S
RNA could be detected  in any of the cell fractions.
This finding  suggests  that any  16S  RNA formed  is
rapidly degraded  in the  presence  of the drug.
Fig.  2  e shows that incorporation  into ribosomal
precursor  molecules  continued  even  after  60  min
of  exposure  to  puromycin  although  the  appear-
ance of 32S  was  slowed compared  to  normal  cul-
tures (Scherrer  et al.,  1963; Warner et al.,  1966 b).
It  is  obvious  from  the  results  in  Fig.  2  that,
while  puromycin  causes  no  great  qualitative
changes  in  the  types of RNA being formed  in  the
nucleus  of treated  cells,  there  is  a  sharp  decrease
in the rate of total incorporation.  This is probably
not due  to a  real decrease  in the rate of RNA syn-
thesis  but to the  lower  specific  activity  attained  in
the  acid-soluble  pool  of  nucleotides  when  puro-
mycin-treated  cells  are  exposed  to  uridine-
3H,  a
phenomenon  to  be  described  elsewhere  (Soeiro,
R.,  and S.  Vaughan. Data in preparation.).  How-
ever, Fig.  3  shows  that  the  defect in  the  synthesis
of  ribosomes  which  is  imposed  by  puromycin  is
separable from its effect on total uridine incorpora-
tion  into RNA.  Cells were  treated  with three con-
centrations  of  puromycin  (5,  20,  and  100  y/ml)
before  being  labeled  with  uridine-
3 H  and  then
were  fractionated  as  described  in  Methods  and
Materials.  It  can be seen  that  cells treated  with 5
y /ml  of  puromycin  incorporate  almost  normal
(>90%  of control)  amounts  of  uridine-3H  into
ribosomal  precursor  RNA  (Fig.  3  a  and  b)  and
that  cells treated  with  20 y/ml  of puromycin  in-
corporate  about one-half as much  as control  (Fig.
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FIGURE  5  Fate  of puromycin  RNA  in presence  of the drug.  HeLa cells  were preincubated  with  puro-
mycin  (100  y/ml)  for 5 min and  then  labeled  with  uridine-
14C for  30  min  (0 time).  An aliquot was  re-
moved, and  the remaining culture  was  treated with actinomlycin  D  (5  y/iml)  and allowed to  incubate  in
the presence  of both  drugs. After  a further  30,  60,  or 90  min,  samples  were taken and fractionated.  The
radioactive  RNA of the nuclear pellet was analyzed as in the previous experiments.  0 time (-- 0--); 30 min
(-O-);  60 min (---);  and 90  min  (--V--).
3 c).  It  is also apparent that treatment  of cells with
20  or  100  y/ml  of  puromycin  completely  pre-
vented  the  cytoplasmic  appearance  of  16S  or  28S
rRNA (Fig.  3 c' and d'). Even 5 y /ml of puromycin
decreased the appearance  of 28S rRNA  (Fig.  3 6').
Thus,  puromycin  produces  a  specific  block(s)  in
ribosomal  manufacture  past  the  stage  of  tran-
scription of 45S ribosomal  precursor RNA.
Fate  of  45S  RN 1 in
Puromycin-Treated Cells
The next  series  of experiments  was  designed  to
determine  whether  the  45S  RNA  formed  in  the
presence  of puromycin  could  be  utilized  to  form
ribosomes  when  puromycin  was  removed.  This
can  be  accomplished  through  the  use  of  both
puromycin  and  actinomycin  D,  a  drug  which
stops further RNA synthesis within 1-2 min (Reich
et  al.,  1961;  Warner  et al.,  1966b).
Fig. 4 shows an experiment  in which puromycin-
treated  cells were labeled for 30 min to accumulate
radioactive  45S  RNA.  Actinomycin  D  was  then
added  to  the  culture.  The  cells  were  washed  free
of  puromycin,  but  actinomycin  was  maintained
in  the  medium.  After  60 min  the  cells  were  frac-
tionated,  and  it  was  found  that  16S  rRNA  had
appeared  in  the  cytoplasm  and  that  28S  rRNA
could  be  detected  in  the nuclear  supernatant.  In
separate  experiments  performed  exactly  as  that
shown  in  Fig.  4,  it  was  found  that  both  the  16S
and  28S  rRNA  observed  in  the  cytoplasm  or
nuclear  supernatant  can in fact  be recovered  from
subribosomal  particles.  In this experiment,  no 28S
rRNA  had  entered  the  cytoplasm  because  of  the
defective  exit of larger  nuclear  subribosomal units
in  the  presence  of  actinomycin  (Girard  et  al.,
1964).  Thus  the  45S  formed  in  the  presence  of
puromycin  can, when  puromycin is removed,  give
rise  to  28S  and  16S  rRNA  without  any  further
RNA synthesis.
As has been  suggested  earlier,  since  no 28S  and
16S rRNA appear in the cytoplasm in the presence
of  puromycin,  they  may  be  destroyed  in  the
nucleus  soon  after  formation.  This possibility  was
also tested with the aid of actinomycin.  Cells which
had  been  labeled  in  the  presence  of  puromycin
were  further  treated with  actinomycin  D to arrest
RNA  synthesis.  The  fate  of the  45S-labeled  RNA
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FIGURE  6  Analysis of puromycin  32S RNA.  A culture
of HeLa cells  was preincubated for 5 min with puromy-
cin  (100 y/ml)  and  then  labeled  continuously  with
uridine-
14C  for  2  hr  in  the presence  of  the  drug.  The
radioactive  puromycin  RNA  was  extracted  from  the
nuclear  pellet  and  cosedimented  with  normal  cyto-
plasmic  RNA  labeled  with 
3H  for  16 hr. The  uridine-
3H-labeled  sample  served  as a  radioactive  marker  for
normal cytoplasmic 28S RNA.
molecules  was then studied after  an additional 30,
60, and 90 min (Fig. 5).  Radioactivity in 45S RNA
decreased  although considerably more slowly than
has  previously  been  observed  in  normal  cells
(Warner  et al.,  1966b).  There was at first  a  slight
increase  in  "32S"  RNA,  but  no  16S  rRNA  was
detected.  Thus there  must be  degradation  of new
16S  rRNA  in  cells  continually  treated  with  puro-
mycin,  since  the  experiment  of  Fig.  4  shows
definitely  that  16S  molecules  can,  upon  the  re-
moval of puromycin, derive from 45S RNA formed
in the presence  of puromycin.
So that nominal  32S RNA, the first larger rRNA
product  of 45S  cleavage,  could  be  distinguished
from  nominal  28S  rRNA,  the  ultimate  product
found  in  the  ribosomes,  a  precise  sedimentation
analysis  was then  carried  out on  the  32S RNA  in
the nucleolus  which  accumulated  in  the  presence
of puromycin.  For this purpose,  cytoplasmic  RNA
from  growing  cells  labeled  overnight  with
uridine-3H  was  mixed  with  the  nucleolar  RNA
from  puromycin-treated  cells  which  had  been
labeled  for  2.5  hr with  uridine-
4C.  Fig.  6  shows
that  some  RNA-14C  cosediments  with  28S  cyto-
plasmic  RNA.  This  implies  that  puromycin  does
not  completely  block  the  development  of  28S
RNA.  Since  the puromycin-treated  cells continue
to make 45S, 32S,  and probably 28S  RNA without
making  subribosomal  particles,  perhaps  the  28S
RNA, like  the  16S,  is degraded.
Lack of Effect  of Puromycin on
RNA  Methylation
In  light  of the  knowledge  that methyl  groups
are incorporated into  the 45S  ribosomal  precursor
RNA  (Greenberg and Penman,  1967; Zimmerman
and  Holler,  1967)  prior  to  its  cleavage  into  32S
and  16S  RNA,  it  was  possible  that  puromycin
exerted  its  blocking  effect  on  proper  ribosomal
maturation by affecting methylation  of 45S RNA.
Therefore,  cells  which had been preincubated for 5
min  with  puromycin  (100  y/ml)  were  labeled
with  methyl-14C-labeled  methionine  for  20  min.
The  degree  of labeling in 45S RNA of (Fig.  7) the
puromycin-treated  cells  was  the  same  as  that  of
the  control  cells.  Two  conclusions  can  be  made
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FIGURE  7  Labeling  of  45S  RNA  with  methyl-1
4C-
labeled  methionine  in  the  presence  of  puromycin.  A
culture  of  HeLa  cells which  had  been  grown  in Eagle's
medium  containing  adenosine  10-4 M was  centrifuged
and  resuspended  in  methionine-free  Eagle's  medium
(50%  dialyzed  horse  serum,  adenosine  10
- 4 M).  The
adenosine  is  used  to  prevent  utilization  of  the  CH3
groups  of  methionine  in  purine  ring synthesis  (Green-
berg  and  Penman,  1967).  After  5  min at 37'C the cul-
ture  was  recentrifuged  and  suspended  in  methionine-
free  Eable's  medium  (plus  adenosine  10-4 M).  The
culture  was  then  divided,  and  one-half  was  incubated
with  puromycin  (100  y/ml).  After  5  min each  culture
was  exposed  to  methyl-1
4C-labeled  methionine  (0.5
tc/ml;  15  /sc/Amole)  for  20  min.  After  10  min  of
incorporation,  an  additional  5%  of  undialyzed  horse
serum  was added to prevent methionine  depletion.  The
nuclear  pellet RNA  was extracted  with hot phenol  and
was  then analyzed  as in Fig.  . control;  0  puromy-
cin treated.
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FIGURE 8  Fate  of  methyl-'
4C-labeled  puromycin
RNA  after  removal  of  drug.  Cells  were  labeled  with
methyl-'
4 C  methionine  as in  the experiment  of  Fig.  7.
After a  30 min period of labeling,  further incorporation
was  stopped  by  the  addition  of  actinomycin  D  (5
y/nml);  the  cells  were  washed  free  of  the puromycin,
and  then  incubated  in  the presence  of actinomycin  D
for  an  additional  60  min.  RNA  was  analyzed  after
phenol  extraction  from  (a)  nuclear  pellet,  (b)  nuclear
supernatant,  (c) cytoplasm.
from  this  experiment.  First,  puromycin  does  not
affect  rRNA  maturation by  grossly disturbing  the
extent  of  methylation.  Second,  the  rate  of  45S
RNA  synthesis  is  not  impaired  by  puromycin,
even  though,  as  has  been  discussed  previously,
uridine incorporation  is lowered by the drug. This
conclusion  is  based on  the  facts  that only  the  new
45S  RNA  molecules  are  receptors  for  methyl
groups and  that the  time  for  the  entire  process of
methylation  and  cleavage  of  45S  requires  only
10-15  min.  Thus,  when  a  culture  treated  with
puromycin for a total of 25 min  was found  to have
exactly  the  same  amount  of  radioactive  methyl
groups in 45S RNA as the control,  it could be con-
cluded  that  continuing  45S  RNA  synthesis  was
not impaired  by the  drug.
A  second  experiment  demonstrates  that  the
same  methyl-labeled  rRNA  precursor  molecules
which  are  formed  in  puromycin-treated  cells  can
in fact  be utilized  in the construction  of ribosomes
when  puromycin  is  removed.  Puromycin-treated
cells  were  labeled  with  methyl-"4C-labeled  methi-
onine  for  30  min;  then  actinomycin  was  added,
and  the  cells  were  washed  free  of the  puromycin.
Subsequently,  radioactivity  from  the  methyl-
labeled  45S  RNA  molecules,  which  had  accumu-
lated  prior  to  addition  of  actinomycin,  appeared
in  16  and 28S  rRNA  (Fig.  8).  It has  been  shown
that  within  5  min of the  addition  of actinomycin
D  there  is  no  further  methyl-1 4C  labeling  of 45S
RNA  (Zimmerman  and  Holler,  1967).  Therefore
in  the  experiment of Fig.  8  extensive  methylation
of  RNA  after  removal  of  puromycin  could  not
have occurred.
This experiment demonstrates that at least  some
45S  molecules  formed  in  puromycin-treated  cells
not  only  have  the  normal  number  of  methyl
groups but probably also have  the  right pattern of
methyl  groups since  it appears  from  other studies
on  ribosome  formation  in  methionine-deficient
cells  (Vaughan,  et al. 1967a)  that  proper  methyla-
tion  is a prerequisite  for ribosomal maturation.
Cycloheximide vs. Puromycin
The  final  series  of experiments  to be  described
in this paper was undertaken  to elucidate  the basis
of the puromycin-induced  block of rRNA  matura-
tion.  Even  when  protein  synthesis  is  reduced  to
less than  1 7,%  of the control  rate by  cycloheximide,
HeLa  cells  are  still capable  of initiating ribosomal
RNA  synthesis  and  completing  the  manufacture
of  ribosomes  from  a  preexisting  pool  of  protein
(Warner et  al.,  1966  a).  Thus  the  defect imposed
by  puromycin  on  rRNA  maturation  cannot  be
due to simple inhibition  of protein  synthesis or to a
depletion  of proteins  essential  to  rRNA  matura-
tion. The  action of puromycin on  protein synthesis
differs  from  cycloheximide  in  a  very  important
respect.  Peptide-bond  formation  continues  in  the
presence of puromycin and results in the formation
of  acid-soluble  peptidyl-puromycin  products
(Nathans,  1964;  Smith  et  al.,  1965)  while  cyclo-
heximide  acts  by  drastically  slowing  the  rate  of
peptide-bond  formation  (Ennis and  Lubin,  1964;
Siegel  and  Sisler,  1964;  Wettstein  et  al.,  1964).
Prior treatment  of cells with  cycloheximide  might
therefore  be  expected  to  inhibit  the  formation  of
these  puromycin  peptides.  It  was  reasoned  that,
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ecAif these  compounds play  a role  in  the puromycin-
induced  block  in  rRNA  maturation,  perhaps  a
prior  treatment  with  cycloheximide  might  allow
ribosome maturation  to occur  even in the  presence
of  puromycin.  HeLa  cells  which  had  received
cycloheximide  for  20  min  and  puromycin  for  15
min  were  "pulsed"  with  uridine-3H  and  chased
with  ribonucleosides  in  the  presence  of  the  two
drugs.  150  min  after  the  chase  nucleosides  had
been added,  cytoplasmic  RNA  in this  and  in  two
similar cultures  which  had  received  only  a  single
drug was  examined  as  before  (Fig.  9).  It  is  clear
that  the  addition  of  cycloheximide  allowed  sub-
stantial  28S  and  16S  RNA  to  emerge  into  the
cytoplasm of puromycin-treated  cells.
The  prevention  of  the  puromycin  blockage  of
rRNA  maturation  by cycloheximide  is  even more
pronounced  if normal  RNA  synthesis  is  allowed
to occur for  15 min (at which time the only labeled
RNA  related  to  ribosomes will  be the  45S RNA)
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FIGURE  10  The effect of  puromycin  on the formation
of  ribosomes  from  normal  RNA  in  the  presence  of
cycloheximide.  HeLa  cells  were  labeled  with  uridine-
a4C  for 8  min  before  the addition  of chase  nucleosides.
After an additional  10 min, the culture  was divided and
puromycin  (100  y/ml)  or  cycloheximide  (150  y/ml)
plus  puromycin  were  added  according  to  the  experi-
mental  plan  outlined  above.  The  cultures  were  incu-
bated  a further  72  min  before  newly  labeled cytoplas-
mic RNA  was examined.
Experimental Plan
Time,  0  8  18  90
Min. .
(a Control ......
Uridine-L
4C.  chase..  tb  puro ........  sample
(c puro +  cyclo. 
5(
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FIGURE  9  Effect  of  cycloheximide  on the  capacity  of
puromycin  to  block  ribosome  formation.  Logarith-
mically  growing  IleLa  cells  were  preincubated  with  a,
cycloheximide  (cyclo),  100 'y/ml for  20 min;  b,  cyclo-
heximide  for  20  min  and puromycin  (puro),  100y/ml
for  15  min;  or  c,  puromycin  for  15  min  before  the
addition  of  uridine-3H.  After  10  min  of labeling  chase
nucleosides  were  added,  and cultures  were  incubated  a
further  140  min  at which  time  cytoplasmic  RNA was
examined.
Experimental Plan
Time, Min...-20  -15  0  +10  150
a Cyclo  ............. 
b  Cyclo ........  purot  ..uridine-3H .. chase..  sample
c .............. puroj
before the addition of the two  drugs. Fig.  10  shows
such  an  experiment  in  which  cycloheximide  plus
puromycin  allow 28S and  16S RNA  to exit to  the
cytoplasm  in almost  one-half  the control  amount.
DISCUSSION
With  the  availability  of  techniques  which  allow
the observation  of several stages in  ribosomal RNA
biosynthesis  and  maturation,  a  re-examination  of
the  puromycin-induced  block  of ribosome  manu-
facture  was  in  order.  The  experiments  to  be
described  in a  separate  paper  (Soeiro,  R., M.  H.
Vaughan,  and J.  E.  Darnell.  Data  in  prepara-
tion.)  indicate  that  puromycin  quickly  depresses
vhe  rate  of uridine  incorporation  into HeLa  cell
RNA  largely  by  preventing  the  entry  of uridine
into the nucleotides of the acid-soluble  pool.  How-
ever,  in  spite of this  pool effect,  the  same  types of
RNA  become  labeled  in  the  puromycin-treated
cell  as  in  normal  cells.  Furthermore,  labeling  of
45S RNA  with methyl-14C-labeled  methionine  in-
dicates  that  ribosomal  precursor  RNA  is  actually
made at the same rate  as control  cells.
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puromycin  has  been  studied  in  several  experi-
ments  by  preventing  further  RNA  synthesis  with
actinomycin.  After removal of puromycin,  the 45S
RNA labeled in  the presence  of the drug either by
uridine  or  by methyl-'
4C-labeled  methionine  can
be  cleaved  to  32S  and  16S  RNA.  Moreover  16S
RNA,  derived  from  the  45S  RNA  made  in  the
presence of puromycin,  enters the cytoplasm where
it may  be found  in  ribosomal  particles.  The  32S
RNA  also  enters  the  normal  maturation  process
appearing  as 28S  RNA in the nuclear  supernatant
particles.  These  experiments  indicate  not  only
that  45S  RNA  is  transcribed,  but  also  that  the
stages of  maturation  associated  with methylation,
the  cleavage  of 45S  RNA  and  the  alteration  of
32S  to  28S  rRNA,  can  proceed  normally  in  the
presence  of puromycin.
The  defect  imposed  by  puromycin  therefore
seems  to  reside  at  the  level  of  conversion  of  a
cleavage  product  of  ribosomal  precursor  RNA
into  a  stable  ribosomal  particle.  Furthermore,  the
data indicate that in the absence of such  a matura-
tion  step  the  RNA  is  degraded.  This  conclusion
follows  from  the  finding  that  the  puromycin-
treated cell continues to synthesize ribosomal RNA
without  accumulating  any  of  the  RNA  species.
Whether  rRNA  degradation  is  an  abnormal  ac-
companiment  of  blocked  ribosomal  maturation
imposed  by this  drug or  the  cell  normally  has  a
mechanism for degradation  of unused or unwanted
ribosomal  RNA  is  impossible  to  answer  at  this
time.  It  is  pertinent  to  point  out,  however,  that
continued  synthesis  and  destruction  of  ribosomal
precursor RNA  rather  than its normal  utilization
have  been found  to occur  in  HeLa  cells  deprived
of  methionine  (Vaughan  et  al.,  196
7a).  It  is
possible  therefore  that over-all  ribosome  synthesis
in these  cells  is regulated  not at the  level  of trans-
cription  of  the  45S  ribosomal  RNA  precursor,
but at the level of the utilization of the products  of
this molecule.
The  final  point of interest in  these  experiments
relates  to  the  mechanism  whereby  one  inhibitor
or protein  synthesis,  puromycin,  effectively blocks
ribosome  maturation  while  another,  cyclohex-
imide, does not. The outstanding,  knowndifference
between  cells  treated with  these  two agents  is that
in  puromycin-treated  cells  small  peptidyl-puro-
mycin  complexes  are continually  being generated
while in cycloheximide-treated  cells  the machinery
for  making proteins  is simply  slowed by  a factor of
50-100. If the synthesis of the peptidyl-puromycin
complexes  is halted  by  the simultaneous  presence
of cycloheximide,  rRNA  maturation  can  proceed
in the  presence of puromycin.  That cycloheximide
does  not  block  the  entry  of  puromycin  into  the
cell  is  suggested  by  the  fact  that  polyribosomes,
normally  stable  when inhibited  by cycloheximide,
are  slowly  disaggregated  when  puromycin  treat-
ment  is  superimposed  (Columbo  et  al.,  1965;
Soeiro,  R. Unpublished results).  These results sug-
gest  that  there  is  no  direct  involvement  of  the
puromycin  molecule  itself  in  blocking  ribosomal
maturation  but  that  a  cellular  product  made  in
the presence of puromycin  could be the responsible
agent.  Since  the  only  known  products  of  puro-
mycin  within  cells  are  puromycin  peptides  or
inactive degradation  products  of puromycin  itself,
it  is  tempting  to  conclude  that  puromycin-pep-
tides  combine  with ribosomal  precursor  RNA  or
newly  generated  28S  and  16S  rRNA  in  such  a
way that  its proper union  with ribosomal protein
is inhibited  and destruction of the RNA follows.
This work was supported by grants from the National
Institutes  of  Health  (CA  07861-03),  the  National
Science  Foundation  (GB  4565),  and  the  Health
Research  Council  of the City of New York.
Dr.  Soeiro  is  a fellow  of the National  Institutes  of
Health.  Dr.  Vaughan  is  a  fellow  of  the  Damon
Runyon  Memorial  Fund  for  Cancer  Research.  Dr.
Darnell  is  a Career Scientist  of the Health  Research
Council  of the  City  of New  York.
Receivedfor publication 4 May  1967, and in revisedform  14
September  1967.
REFERENCES
COLUMBO,  B.,  L.  FELICETTI,  and C.  BAGLIONI.  1965.
Inhibition  of protein synthesis by cycloheximide  in
rabbit  reticulocytes.  Biochem.  Biophys.  Res.  Commun.
18:389.
EAGLE,  H.  1959.  Amino  acid  metabolism  in  mam-
malian  cell  cultures.  Science.  130:432.
ENNIs,  H.,  and  M.  LuBIN.  1964.  Ciycloheximde:
aspects  of inhibition  of protein  synthesis  in  mam-
malian cells.  Science.  146:1474.
GIRARD,  M.,  H.  LATHAM,  S.  PENMAN,  and  J.  E.
DARNELL.  1965.  Entrance  of newly  formed  messen-
ger RNA  and ribosomes into HeLa cell  cytoplasm.
J.  Mol.  Biol.  11:187.
GIRARD,  M.,  S.  PENMAN,  and  J.  E.  DARNELL.  1964.
100  THE  JOURNAL  OF  CELL  BIOLOGY  VOLUME  36,  1968The effect of actinomycin  on ribosome formation in
HeLa cells.  Proc. Natl. Acad.  Sci.  U.S. 51:205.
GREENBERG,  H.,  and  S.  PENMAN.  1967.  Methylation
and  processing  of ribosomal  RNA  in HeLa  cells.
KNIGHT,  E., JR.,  and J.  E.  DARNELL.  1967.  Distribu-
tion of  5 sRNA in HeLacells.  J.  Mol. Biol. 28:491.
LATHAM,  H.,  and J.  E.  DARNELL.  1965.  Entrance  of
mRNA  into  HeLa  cell  cytoplasm  in  puromycin
treated cells.  J.  Mol. Biol.  14:13.
NATHANS,  D.  1964.  Puromycin  inhibition  of protein
synthesis:  incorporation  of puromycin  into peptide
chains.  Proc. Natl. Acad. Sci.  U.S.  51:585.
PENMAN,  S.  1966.  RNA metabolism in the HeLa cell
nucleus.  J.  Mol. Biol.  17:117.
PENMAN,  S.,  Y.  BECKER,  and J.  E.  DARNELL.  1964.
A  cytoplasmic  structure  involved  in  the  synthesis
and  assembly  of  poliovirus  components.  J.  Mol.
Biol.  8:541.
PENMAN,  S.,  I. SMITH,  and E. HOLTSMAN.  1966.  Ribo-
somal  RNA  synthesis  and  processing  in  a particu-
late site  in the  HeLa cell nucleus.  Science.  154:786.
PERRY,  R.  P.  1964.  Role  of the  nucleolus  in  ribo-
nucleic  acid  metabolism  and  other  cellular
processes.  Natl. Cancer Inst. Monograph.  14:73.
RAKE,  A.  V.,  and  A.  F.  GRAHAM.  1964.  Kinetics of
incorporation  of  uridine  1
4C  into  L  cell  RNA.
Biophys.  J.  4:267.
REICH,  E., R.  M.  FRANKLIN,  A. J.  SHATKIN,  and E. L.
TATUM.  1961.  Effect  of actinomycin  D on cellular
nucleic  acid  synthesis  and  virus  production.
Science.  134:556.
ROSSET,  R.,  R.  MONIER,  and  J.  JULIEN.  1964.  Les
ribosomes  d'  Escherichia coli.  I.  Mise  en  evidence
d'un RNA ribosomique de faible poids  moleculaire.
Bull. Soc.  Chim. Biol. 46:87.
SCHERRER,  K., H.  LATHAM,  and J.  E. DARNELL.  1963.
Demonstration  of  an  unstable  RNA  and  of  a
precursor  to  ribosomal  RNA  into  HeLa  cells.
Proc. Natl. Acad. Sci. U.S. 49:240.
SIEGEL,  M.  R.,  and  H.  D.  SISLER.  1964.  Inhibition
of  protein  synthesis  in  vitro  by  cycloheximide.
Nature.  200:675.
SMITH,  J. D.,  R.  R.  TRAUT,  G. M.  BLACKBURN,  and
R.  E.  MONRO.  1965.  Action  of  puromycin  in
poly-adenylic  acid  directed  poly-lysine  synthesis.
J.  Mol.  Biol. 13:617.
SOEIRO,  R.,  H.  C.  BIRNBOIM,  and  J.  E.  DARNELL.
1966.  Rapidly  labeled  HeLa cell nuclear RNA  11.
J.  Mol. Biol.  19:349.
WARNER,  J.  1966.  The  assembly  of  ribosomes  in
HeLa  cells.  J.  Mol. Biol.  19:383.
WARNER,  J.,  M.  GIRARD,  H.  LATHAM,  and  J.  E.
DARNELL.  1966 a.  Ribosome  formation  in  HeLa
cells  in  the  absence  of  protein  synthesis.  J.  Mol.
Biol.  19:373.
WARNER,  J.  R.,  R.  SOEIRO,  H.  C.  BIRNBOIM,  M.
GIRARD,  and  J.  E.  DARNELL.  1966b.  Rapidly
labeled  HeLa  cell  nuclear  RNA  I.  J.  Mol.  Biol.
19:349.
WETTSTEIN,  F.,  H.  NOLL,  and  S.  PENMAN.  1964.
Effect  of  cycloheximide  on  ribosomal  aggregates
engaged  in  protein  synthesis  in vitro.  Biochim.  Bio-
phys.  Acta.  87:525.
VAUGHAN,  M.,  R.  SOEIRO,  J.  WARNER,  and  J.  E.
DARNELL.  1967a.  Proc.  Natl.  Acad.  Sci.  U.S.  In
press.
VAUGHAN,  M.,  J.  WARNER,  and  J.  E.  DARNELL.
1967 b.  Ribosomal precursor  particles  in the  HeLa
cell nucleus. J.  Mol. Biol. 25:235.
ZIMMERMAN,  E.  F., and  B.  W.  HOLLER.  1967.  Methy-
lation  of 45S  ribosomal  RNA  precursor  in  HeLa
cells.  J.  Mol.  Biol. 23:149.
R.  SOEIRO,  M.  H.  VAUGHAN,  AND  J.  E.  DARNELL  Puromycin in  Ribosome Biosynthesis 101